目的 探讨棕榈酸帕利哌酮治疗精神分裂症的疗效与安全性。方法 选取36例精神分裂症患者为实验组, 同时选择与实验组诊断相同、阳性与阴性症状量表(PANSS)评分差异≤5分的33例为对照组。实验组给予肌内注射棕榈酸帕利哌酮, 每月1次;对照组给予口服帕利哌酮, 1次/d, 1周内逐步加至9 mg/d。观察两组治疗前后PANSS评分、显效率及不良事件发生情况。结果 实验组和对照组治疗后PANSS评分与基线比较, 均降低, 差异有统计学意义(F=307.8, P<0.01);两组间比较, 差异无统计学意义(F=3.557, P=0.06)。治疗24周后, 实验组显效26例, 显效率为81.3%, 无一例复发, 对照组显效27例, 复发1例, 显效率为84.4%, 两组显效率比较, 差异无统计学意义;两组不良事件发生率比较差异无统计学意义。结论 注射用棕榈酸帕利哌酮治疗精神分裂症效果明显, 与口服帕利哌酮疗效相当, 且不良反应较轻, 可作为精神分裂症治疗的一种良好选择。
Abstract
Objective To evaluate the safety and efficacy of paliperidone palmitate in the treatment of schizophrenia. Methods 36 patients with schizophrenia were recruited as study group, while another 33 patients with the same diagnosis, same sex, age differences≤5 and PANSS score differences≤5 were as control group. The study group was given paliperidone palmitate by intramuscular injection every month; while the control group was given paliperidone tablets once a day per os, and the dose was gradually increased to 9 mg/d within one week. The PANSS score, efficacy and adverse events were observed in the two groups. Results The PANSS scores at different times before and after treatment in the two groups showed significantly differences (F=307.8, P<0.01) ; while the decreased score of PANSS between the two groups showed no significant difference (F=3.557, P=0.06); 24 weeks after treatment, 26 cases in the study group showed effecacy, with an effective rate of 81.3%, no case relapsed; 26 cases in the control group showed effecacy, 1 case recurred, with an effective rate of 84.4%, The difference of effective rate between the two groups was not statistically significant (P=0.740); the incidence of adverse events was no statistically significant (P=0.800). Conclusions The effecacy of paliperidone palmitate in schizophrenia is quite obvious, and is not inferior to oral paliperidone, and its adverse reactions are few, it is a good choice to use paliperidone palmitate as a treatment of schizophrenia.
关键词
棕榈酸帕利哌酮 /
精神分裂症 /
治疗
Key words
paliperidone palmitate /
schizophrenia /
treatment
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 宓为峰, 邹连勇, 李梓萌, 等. 精神分裂症患者用药依从性及复发情况的调查[J]. 中华精神科杂志, 2012, 45(1): 25-28.
[2] Sapra M, Vabia I V, Reyes P N, et al. Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia[J]. Schizophr Res, 2008, 106(2-3): 348-355.
[3] 刘增龙, 崔利军, 苏丽惠, 等. 经络氧疗法联合利培酮治疗难治性精神分裂症对照研究[J]. 中国全科医学, 2010, 13(2): 546-547.
[4] 段武刚, 曾德志, 徐良雄, 等. 齐拉西酮和氯氮平治疗女性精神分裂症的疗效比较[J]. 海南医学院学报, 2010, 16(6): 771-773.
[5] McEvoy J P. Risks versus benefits of different types of long-acting injectable antipsychotics [J]. J Clin Psychiatry, 2006, 67(5): 15-18.
[6] Citrome L. Paliperidone palmitate-review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication[J]. J Clin Pract, 2010, 64(2): 216-239.
[7] Keith S J, Kane J M, Turner M, et al. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics[J]. J Clin Psychiatry, 2004, 65(1): 120-131.
[8] Nasrallah H. The case for long-acting antipsychotic agents in the post-CATIE era [J]. ActaPsychiatr Scand, 2007, 115(4): 260-267.
[9] 戴梅竹, 张钰成, 陈士华. 帕利哌酮联合帕罗西汀对精神分裂症阴性症状的影响[J]. 中国实用神经疾病杂志, 2013, 16(21): 81-82.
[10] Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study[J].J Clin Psychopharmacol, 2007, 27(1): 6-14.
[11] Sliwa J K, Bossie C A, Ma Y W, et al. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone[J]. Schizophr Res, 2011, 132(1): 28-34.
[12] Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia[J]. Prog Neuro-psychopharmacol Biol Psyc-hiatry, 2011, 35(4): 1002-1008.
[13] 刘文芳, 姜文亮, 付德兴, 等. 抗精神分裂症药帕利哌酮研究进展[J]. 中国医药, 2012, 7(4): 516-518.
PDF(680 KB)
